SLC5A2 and chronic kidney disease: Furthermore, in the exploratory analyses, we identified that the benefit of SGLT2 inhibitors on AF risk reduction was significant in men and the non-Hispanic White group, as well as among the most susceptible individuals with established ASCVD or CKD.